Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menitorix + Infanrix IPV
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Menitorix + Infanrix IPV refers to the co-administration of two GlaxoSmithKline vaccines: Menitorix (a combined Haemophilus influenzae type b and Meningococcal group C conjugate vaccine) and Infanrix IPV (a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine). Menitorix provides active immunization against Hib and Neisseria meningitidis serogroup C by using capsular polysaccharides conjugated to a tetanus toxoid carrier. Infanrix IPV provides protection against diphtheria, tetanus, pertussis, and poliomyelitis using a combination of toxoids, purified bacterial proteins, and inactivated viral particles. This specific regimen was evaluated in Phase IIIb clinical trials to assess the immunogenicity and safety of booster doses in preterm and full-term infants, often administered alongside other pediatric vaccines such as the pneumococcal conjugate vaccine (Prevenar).
- Brand names
- MenitorixInfanrix IPV
- Other names
- Infanrix IPV-GlaxoSmithKline-Haemophilus influenzae type b infection-meningococcal diseaseMenitorix co-administered with Infanrix IPV
02
Targets
PRN (Pertactin)Diphtheria toxinPRNP (Cellular Prion Protein)Neisseria meningitidis group C capsular polysaccharideTT (Tetanus toxoid)FHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on Menitorix + Infanrix IPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Menitorix + Infanrix IPV.